News & Events about Roivant Sciences Ltd.
Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ETRoivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd Annual Health Care Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 30, ...
Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems? Thinking about buying stock in Prometheus Biosciences, Meta Materials, Eterna Therapeutics, Roivant Sciences, or China Automotive Systems? PR Newswire NEW YORK...
Globe Newswire
2 months ago
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosisRVT-3101 is currently being evaluated in a large global Phase 2b ...
Ticker Report
2 months ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) Director Financial Lp Qvt sold 5,656,081 shares of the stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following the transaction, the ...
Globe Newswire
2 months ago
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for ...